The CRCM is one of the most heavily funded structures of the ARC Foundation.
In 2023, the CRCM was one of the top 10 organisations funded by the ARC Foundation. The latter contributed to the funding of 7 new research projects and support initiatives for a total amount of €2,177,976.
3 Individual grants for young researchers
- Damien BRUYAT (Master 2 – Team Immunity and Cancer): Evaluation of the prognostic role of circulating microparticulate forms of BTN2A1 in patients with hormone-sensitive metastatic prostate cancer.
- Alix JAEGER (PhD student – Team Targeting signalling networks and microenvironment in cancer): Study of the role of Protein Tyrosine Kinase 7 (PTK7) in the pathophysiological functions of dendritic cells.
- Matias ESTARAS (Post-doctoral fellow – Team Translational Research and Therapeutic Targets in Pancreatic Cancer): Development of new inhibitors of stress granule components to treat Kras-induced pancreatic adenocarcinoma.
1 Fondation ARC project
- Fabienne BRENET (Team Signalling, Haematopoiesis and Mechanisms of Oncogenesis): Deciphering the functions of the metabolite 3-hydroxy-kynurenine in KIT-dependent oncogenic progression.
2 programmes accredited by the Fondation ARC
- Flavio MAINA (Team Targeting signalling networks and microenvironment in cancer): Searching for vulnerabilities at early and advanced stages to target cancer cells and immune cells in liver cancer models.
- Xavier MORELLI (Team Integrative Structural and Chemichal Biology): Deciphering and exploiting synthetic lethality links with the nucleotide synthesis rescue pathway in T-ALL.
1 PANCREAS project
- Brice CHANEZ (Team Translational Research and Therapeutic Targets in Pancreatic Cancer): NeoPREDICT: a multicentre phase II trial to personalise neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma using a transcriptomic signature.
We congratulate all the winning researchers for their commitment and the Fondation ARC for their support.